News, stories and opinions for the business innovators of the world.

BluSense Diagnostics adopts PI’s NeoSync to remotely monitor and manage its fleet of point-of-care diagnostic instruments

Roger LangsdonMarketing Director

BluSense Diagnostics (BluSense), a global diagnostics company, has announced it has adopted Planet Innovation’s (PI) NeoSync connectivity solution to remotely monitor its fleet of in-market diagnostic instruments.

BluSense provides patients and healthcare professionals with quick and accurate infectious disease and clinical biomarker diagnostic tests via its portable diagnostic instrument, BluBox, and its one-drop-of-blood ViroTrack microfluidic cartridges, performing proprietary quantitative immuno-magnetic assays (IMA).

By using NeoSync, BluSense has gained real-time insights into the performance and usage of its deployed devices, along with gaining access to instrument logs remotely. These features enable BluSense to provide superior end-user support.

John McCormack, BluSense CTO, explained: “As our fleet of deployed instruments grows, it is very valuable for us to remotely understand how each instrument is performing, including knowing its test count and consumable use. NeoSync was integrated in just a few weeks and will improve our device’s uptime while significantly reducing support costs. As we expand our patented IMA technology to new assays, like our upcoming Vitamin D test, it is great to know that we have a connectivity solution in place that can scale with us.

“The improved connectivity also provides great benefits for BluSense’s customers. End-users can achieve live device QC status for early problem solving, disclose training needs based on user error statistics, execute remote troubleshooting, receive automatic over-the-air software updates and access a seamless, GDPR-compliant EHR/LIS integration.”

Sam Lanyon, Co-founder and GM Innovation Services at Planet Innovation, commented: “NeoSync is part of the suite of PI Platforms we offer all our clients to help them get to market faster and support their customers better. For BluSense, NeoSync allows them to unlock a range of insights into how their products are working in the field and offer a deeper understanding of user behavior, all via the simple Vendor Portal.”

BluSense is currently using NeoSync to monitor over 30 different metrics, including the instrument configuration, for each device. It is also able to analyze reader logs remotely to better understand the behavior of readers out in the field and more efficiently address customer feedback.

Learn more about NeoSync.


Roger Langsdon Marketing Director
Roger Langsdon

Roger is the Marketing Director at Planet Innovation and a specialist marketing and communications professional with a focus on growing an organization’s reputation and revenue through strategic marketing and high-impact communications.

Roger Langsdon

Sign up for the Perspectives newsletter:

A roundup of the latest news and opinions from PI.

Related Articles.

Remote patient monitoring image

PI Launches NeoSync™ to transform point-of-care connectivity


Planet Innovation has launched NeoSync™, a unique, out-of-the box product that connects medical devices to popular Electronic Health Records (EHRs).

Remote patient monitoring image

Medical device vendors no longer left in the dark thanks to NeoSync™ connectivity solution


Until now, many device vendors have had limited, if any, remote visibility into their products.

Remote patient monitoring image

PI’s NeoSync™ connectivity solution wins Good Design Award


PI’s Digital team picked up a prestigious Good Design Award Winner Accolade in the Digital Design category at the 2022 Australian Good Design Awards, for its NeoSync: Transforming Point-of-Care Testing connectivity solution.

Remote patient monitoring image

How to build a regulated remote patient monitoring product that clinicians and patients will actually use


With the COVID-19 pandemic shining a light on the benefits of telehealth, there has never been a better time to be in remote patient monitoring (RPM). But if you’re going to be successful, you need to win over your two main users: patients and clinicians.